News | July 19, 2023
SEBI approves Piramal Pharma’s Rs 1,050-crore rights issue
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Advances clinical research capabilities with leading regulatory grade registries platform
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
The acquisition of ADL BioPharma now makes WACKER owner of the entire plant, with total fermentation capacities of just under 3,000 cubic meters
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
Allianz is ISO 9001:2015 certified and INVIMA certified for storage, sampling, dispensation, and distribution of APIs to the Colombian market
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Subscribe To Our Newsletter & Stay Updated
